PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.37%
EBIT growth 0-5% – Limited. Howard Marks would worry if rising SG&A or R&D is constraining profitability.
-2.64%
Negative operating income growth means rising costs or falling revenues are eroding core profitability. Benjamin Graham would raise caution.
0.38%
Net income growth 0-5% – Barely inching up. Howard Marks would be wary of overhead or macro pressure limiting profitability gains.
3.04%
EPS growth 0-5% – Weak but still positive. Howard Marks would remain cautious, suspecting limited pricing power or cost pressures.
3.04%
Diluted EPS growth 0-5% – Minimal improvement. Howard Marks would remain cautious about further dilution or flat net income.
2.54%
Share count up to +3% – Slight dilution. Howard Marks would be cautious but might accept it if used for profitable growth investments.
2.54%
Diluted share count up to +3% – Modest dilution. Howard Marks might tolerate it if used for high-ROI projects or strategic acquisitions.
No Data
No Data available this quarter, please select a different quarter.
10.47%
OCF growth 10-15% – Solid. Seth Klarman would check consistency across several periods to confirm it’s not a one-off spike.
10.65%
FCF growth 10-15% – Solid. Seth Klarman would confirm consistency and see if the firm reinvests or returns capital effectively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12900.29%
A negative 10Y OCF/share CAGR signals erosion in long-term cash generation. Benjamin Graham would label this as a major red flag.
-37006.68%
A negative 5Y OCF/share CAGR indicates declining cash generation per share mid-term. Benjamin Graham would see this as a red flag unless explained by short-term strategic investments.
-70.29%
Negative 3Y OCF/share CAGR shows recent erosion in operating cash. Benjamin Graham would see this as a cautionary signal unless explained by strategic investments.
-15642.97%
A negative 10Y net income/share CAGR reflects a decade of weakening profits. Benjamin Graham would be extremely cautious unless a turnaround is evident.
-43858.45%
A negative 5Y net income/share CAGR reveals a mid-term deterioration in bottom-line earnings. Benjamin Graham would be cautious unless a credible turnaround is visible.
-130.01%
Negative 3Y net income/share CAGR highlights recent bottom-line decay. Benjamin Graham would want clarity on cost vs. revenue drivers for the declines.
No Data
No Data available this quarter, please select a different quarter.
4179.35%
5Y equity/share CAGR above 12% – Strong mid-term book value expansion. Warren Buffett would see if steady profits and moderate payout ratios sustain this pace.
1066.60%
3Y equity/share CAGR above 12% – Excellent recent net worth expansion. Warren Buffett would check consistent earnings retention or beneficial buybacks driving this growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-19.98%
Negative asset growth may reflect divestitures or depreciation outpacing new investments. Benjamin Graham wonders if shedding non-core assets improves focus or signals trouble.
-27.26%
Falling book value/share indicates net losses, large dividends, or intangible impairments. Benjamin Graham warns unless there’s a strategic reason.
-100.00%
A negative growth rate in debt means deleveraging, often positive for conservative investors. Benjamin Graham confirms it doesn’t restrict needed investments.
37.07%
R&D growth above 30% – Very high. Philip Fisher demands clear benefits or milestone achievements to justify the spending surge.
-49.28%
Shrinking SG&A can raise profits short term, but might risk cutting key growth drivers. Benjamin Graham sees if this is sustainable.